文献速递泌尿男性生殖肿瘤

前列腺癌临床试验中种族和民族少数群体及老年人纳入差异的Meta分析

Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis.
PubMed 文献 · JAMA Oncol · 2023-01-01

这项Meta分析检索了MEDLINE、Embase和ClinicalTrials.gov截至2021年2月的前列腺癌临床试验,评估种族、民族和年龄亚组的纳入差异。美国试验中黑人和西班牙裔患者的纳入发生率比均为0.70(95%CI 0.59-0.83),显著低于其发病构成;老年人纳入无差异(EIR 1.00;95%CI 0.95-1.05)。大型试验中黑人代表比例更低(meta回归系数-0.06;95%CI -0.10至-0.02;P=0.002)。

要点

  • 美国前列腺癌试验中黑人和西班牙裔患者纳入发生率比均为0.70(95%CI 0.59-0.83),显著低于其发病构成。
  • 老年人(≥65岁)纳入无差异:试验比例71.1%,EIR 1.00(95%CI 0.95-1.05)。
  • 大型试验中黑人患者代表比例更低(meta回归系数-0.06;95%CI -0.10至-0.02;P=0.002)。

核心结论

  • Black and Hispanic men are underrepresented in trials compared with their share of PCa incidence.
  • The representation of Black patients has consistently remained low during the past 2 decades.

研究设计与样本

  • 系统检索MEDLINE、Embase和ClinicalTrials.gov从建库至2021年2月的前列腺癌临床试验主要报告。
  • 所有2/3期随机前列腺癌临床试验纳入年龄差异分析;仅在美国招募的试验纳入主要种族和民族差异分析。

主要发现

  • 在报告种族的试验中,9552例参与者中954例(10.8%)为非洲裔美国人/黑人,80例(1.5%)为亚洲/太平洋岛民,8518例(78.5%)为白人。
  • 65项美国试验中,45项(69.2%)报告了种族,仅9项(13.8%)报告了全部5个美国种族类别的数据。
  • 286项全球试验中,75项(26.2%)报告了老年人的纳入比例;分别有2项(3.1%)和41项(15.0%)试验报告了按种族和年龄的结果。
  • 美国试验中黑人(EIR 0.70;95%CI 0.59-0.83)和西班牙裔(EIR 0.70;95%CI 0.59-0.83)患者显著代表性不足;老年人代表性无差异(TP 21143[71.1%];EIR 1.00;95%CI 0.95-1.05)。
  • 大型试验中黑人患者代表性更低(meta回归系数-0.06;95%CI -0.10至-0.02;P=0.002)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Prostate cancer (PCa) is marked by disparities in clinical outcomes by race, ethnicity, and age. Equitable enrollment in clinical trials is fundamental to promoting health equity. OBJECTIVE: To evaluate disparities in the inclusion of racial and ethnic minority groups and older adults across PCa clinical trials. DATA SOURCES: MEDLINE, Embase, and ClinicalTrials.gov were searched to identify primary trial reports from each database's inception through February 2021. Global incidence in age subgroups and US population-based incidence in racial and ethnic subgroups were acquired from the Global Burden of Disease and Surveillance, Epidemiology, and End Results 21 incidence databases respectively. STUDY SELECTION: All phase 2/3 randomized PCa clinical trials were eligible for age disparity analyses. Trials recruiting exclusively from the US were eligible for primary racial and ethnic disparity analyses. DATA EXTRACTION AND SYNTHESIS: This study was reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines. Data were pooled using a random-effects model. MAIN OUTCOMES AND MEASURES: Enrollment incidence ratios (EIRs), trial proportions (TPs) of participants 65 years or older or members of a racial and ethnic subgroup divided by global incidence in the corresponding age group, or US population-based incidence in the corresponding racial and ethnic subgroup, were calculated. Meta-regression was used to explore associations between trial characteristics and EIRs and trends in EIRs during the past 3 decades. RESULTS: Of 9552 participants among trials reporting race, 954 (10.8%) were African American/Black, 80 (1.5%) were Asian/Pacific Islander, and 8518 (78.5) were White. Of 65 US trials, 45 (69.2%) reported race and only 9 (13.8%) reported data on all 5 US racial categories. Of 286 global trials, 75 (26.2%) reported the enrollment proportion of older adults. Outcomes by race and age were reported in 2 (3.1%) and 41 (15.0%) trials, respectively. Black (EIR, 0.70; 95% CI, 0.59-0.83) and Hispanic (EIR, 0.70; 95% CI, 0.59-0.83) patients were significantly underrepresented in US trials. There was no disparity in older adult representation (TP, 21 143 [71.1%]; EIR, 1.00; 95% CI, 0.95-1.05). The representation of Black patients was lower in larger trials (meta-regression coefficient, -0.06; 95% CI, -0.10 to -0.02; P = .002). CONCLUSIONS AND RELEVANCE: The results of this meta-analysis suggest that Black and Hispanic men are underrepresented in trials compared with their share of PCa incidence. The representation of Black patients has consistently remained low during the past 2 decades.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Riaz IB, Islam M, Ikram W, et al. Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis. JAMA Oncol. 2023. PMID: 36416812. doi:10.1001/jamaoncol.2022.5511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。